
The spectrum of cardiac zzso of cancer chemotherapy has expanded with the development of zzso zzso and targeted zzso Their administration in multiple regimens has increased zzso including in older patients and in patients with cardiovascular and/or coronary artery disease zzso zzso toxicity of zzso involves zzso stress and zzso Early detection combines zzso and/or zzso zzso and recent methods such as tissue zzso imaging, strain rate zzso and sampling of serial zzso and/or zzso zzso zzso has proven effective in the prevention of zzso toxicity in children and zzso High doses of the zzso drugs zzso and zzso may result in a zzso heart failure and in life-threatening zzso zzso zzso induced by the zzso zzso and zzso impacts prognosis of patients with prior zzso Severe zzso may complicate administration of zzso zzso zzso therapies with the zzso zzso zzso zzso zzso zzso and, to a lesser extent, zzso induce heart failure or zzso zzso dysfunction in zzso and zzso zzso zzso and zzso induce zzso whereas zzso may promote severe hypertension and zzso zzso Small zzso zzso zzso may also elicit zzso dysfunction, in only few patients treated with zzso zzso but in a substantially higher proportion of those receiving the zzso zzso inhibitor zzso or the recently approved drugs zzso zzso and zzso Management of patients at increased cardiovascular risk associated with advancing age, previous zzso or targeted therapies may be zzso by referral to a zzso in a zzso zzso 

